Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017511 · ClinicalTrials.gov registry record · Phase 3
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00017511 is a Phase 3 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00017511, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.
Interventions
- DRUG cevimeline hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017511
The ClinicalTrials.gov registry entry for NCT00017511 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cevimeline hydrochloride is the first listed.
NCT00017511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017511 about?
NCT00017511 is a clinical study titled "Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer". RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effe...
What is the current status of trial NCT00017511?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-06. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00017511?
The interventions under investigation include: cevimeline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00017511?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.